Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608322 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
A Phase 3 study, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT00608322 is a Phase 3 study that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 49 participants.
The verdict
NCT00608322, a Phase 3 study, has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
Interventions
- DRUG Inhaled nitric oxide
- OTHER Sham inhaled nitric oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608322
The ClinicalTrials.gov registry entry for NCT00608322 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of General Medical Sciences (NIGMS), which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhaled nitric oxide is the first listed.
NCT00608322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608322 about?
NCT00608322 is a clinical study titled "Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis". The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
What is the current status of trial NCT00608322?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2009-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00608322?
The interventions under investigation include: Inhaled nitric oxide (DRUG), Sham inhaled nitric oxide (OTHER).
Who is sponsoring clinical trial NCT00608322?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.